MX2022013738A - Ensayo de anticuerpos neutralizantes para proteinas terapeuticas. - Google Patents

Ensayo de anticuerpos neutralizantes para proteinas terapeuticas.

Info

Publication number
MX2022013738A
MX2022013738A MX2022013738A MX2022013738A MX2022013738A MX 2022013738 A MX2022013738 A MX 2022013738A MX 2022013738 A MX2022013738 A MX 2022013738A MX 2022013738 A MX2022013738 A MX 2022013738A MX 2022013738 A MX2022013738 A MX 2022013738A
Authority
MX
Mexico
Prior art keywords
therapeutic proteins
neutralizing antibody
antibody assay
neutralizing antibodies
present
Prior art date
Application number
MX2022013738A
Other languages
English (en)
Inventor
Manoj Rajadhyaksha
Michael Partridge
Aynur Hermann
Susan Irvin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022013738A publication Critical patent/MX2022013738A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere generalmente a los métodos de prueba para la presencia de anticuerpos neutralizantes (NAb) contra las proteínas terapéuticas. En particular, la presente invención se refiere al uso de agentes mitigantes contra fármacos competidores interferentes en ensayos de unión a ligandos o ensayos basados en células para la detección de anticuerpos neutralizantes contra proteínas terapéuticas.
MX2022013738A 2020-05-01 2021-04-30 Ensayo de anticuerpos neutralizantes para proteinas terapeuticas. MX2022013738A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063018821P 2020-05-01 2020-05-01
US202063041768P 2020-06-19 2020-06-19
US202163172488P 2021-04-08 2021-04-08
PCT/US2021/030099 WO2021222711A1 (en) 2020-05-01 2021-04-30 Neutralizing antibody assay for therapeutic proteins

Publications (1)

Publication Number Publication Date
MX2022013738A true MX2022013738A (es) 2022-11-16

Family

ID=76012048

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013738A MX2022013738A (es) 2020-05-01 2021-04-30 Ensayo de anticuerpos neutralizantes para proteinas terapeuticas.

Country Status (11)

Country Link
US (2) US20210341487A1 (es)
EP (1) EP4143573A1 (es)
JP (1) JP2023524062A (es)
KR (1) KR20230005936A (es)
CN (1) CN115867808A (es)
AU (1) AU2021263487A1 (es)
BR (1) BR112022021039A2 (es)
CA (1) CA3180569A1 (es)
IL (1) IL297783A (es)
MX (1) MX2022013738A (es)
WO (1) WO2021222711A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214960A1 (en) * 2022-05-02 2023-11-09 Regeneron Pharmaceuticals, Inc. Biochemical assays for therapeutic proteins
WO2024064044A1 (en) * 2022-09-23 2024-03-28 Merck Sharp & Dohme Llc Neutralization antibody assay method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006127517A2 (en) * 2005-05-20 2006-11-30 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
BR112016009460B1 (pt) * 2013-10-31 2020-09-29 Regeneron Pharmaceuticals, Inc. Método para detectar a presença de anticorpos neutralizantes
DK3105592T3 (en) * 2014-02-11 2019-02-04 Genzyme Corp PROCEDURES FOR DETERMINING THE PRESENCE OR THE QUANTITY OF AN ANTI-MEDICINE ANTIBODY
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
US9995753B2 (en) * 2015-09-25 2018-06-12 Merck Sharp & Dohme Corp. Anti-pembrolizumab antibodies
JP7474240B2 (ja) * 2018-08-03 2024-04-24 ブリストル－マイヤーズ スクイブ カンパニー 抗薬物抗体を検出するための方法

Also Published As

Publication number Publication date
US20220260577A1 (en) 2022-08-18
US20210341487A1 (en) 2021-11-04
EP4143573A1 (en) 2023-03-08
JP2023524062A (ja) 2023-06-08
CA3180569A1 (en) 2021-11-04
BR112022021039A2 (pt) 2022-12-06
AU2021263487A1 (en) 2022-11-17
KR20230005936A (ko) 2023-01-10
CN115867808A (zh) 2023-03-28
WO2021222711A1 (en) 2021-11-04
IL297783A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
MX2009004460A (es) Inmunoensayo de analitos en muestras que contienen anticuerpos anti-analito endogenos.
ATE438853T1 (de) Diagnostische testvorrichtung
Emara et al. Retagging identifies dendritic cell-specific intercellular adhesion molecule-3 (ICAM3)-grabbing non-integrin (DC-SIGN) protein as a novel receptor for a major allergen from house dust mite
MX344053B (es) Metodos para determinar isotipos de anticuerpos anti-farmacos.
MX2014001377A (es) Metodo para detectar cancer pancreatico.
MX2022013738A (es) Ensayo de anticuerpos neutralizantes para proteinas terapeuticas.
JO3812B1 (ar) أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1)
JP2015533788A5 (es)
TW200741203A (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
MX2019006098A (es) Ensayo de anticuerpos.
AR063125A1 (es) Ensayo elisa para la deteccion de vegf
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
PH12020551371A1 (en) Assays to detect neurodegeneration
MX2020000186A (es) Ensayos para evaluar los niveles de anticuerpos neutralizantes en sujetos tratados con un fármaco biológico y usos de los mismos en medicina personalizada.
WO2005036123A3 (en) Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte
MX2021000331A (es) Metodos para mitigar la interferencia de la diana farmacologica en un inmunoensayo de anticuerpos antifarmaco (ada).
MX2008000282A (es) Anticuerpos monoclonales, lineas celulares de hibridomas, metodos y kits para la deteccion de fitasa.
EA201370030A1 (ru) Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням
HK1080091A1 (zh) 用於單獨測定scca同形異構體的免疫測定法
CN110716050A (zh) 抗原组合在制备用于肺癌相关自身抗体检测的试剂盒中的用途以及相应的试剂盒和检测方法
Huber et al. Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer
Abdool et al. Circulating CD33 and its clinical value in acute leukemia
Álvarez-Fernández et al. Serological immune response against ADAM10 pro-domain is associated with favourable prognosis in stage III colorectal cancer patients
Haverland et al. Immunoreactivity of anti-gelsolin antibodies: implications for biomarker validation